New approaches in the treatment of myelofibrosis

Bryan T. Hennessy, Deborah A. Thomas, Francis J. Giles, Hagop Kantarjian, Srdan Verstovsek*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Myelofibrosis with myeloid metaplasia (MMM) is a chronic clonal neoangiogenesis disorder characterized by bone marrow fibrosis and neoangiogensis with extramedullary hematopoiesis. Identification of prognostic factors associated with MMM have not impacted the treatment of the disease, which continues to be palliative with the exception of allogeneic stem cell transplantation (SCT) for potential long-term disease-free survival in selected patients. Additional insights into the pathophysiology of MMM have resulted in the use of novel therapeutic strategies in the treatment of this disease. The rationale for the investigation of these agents in MMM and the status of clinical trials with various modalities such as angiogenesis inhibitors (e.g., thalidomide), tyrosine kinase inhibitors (e.g., imatinib mesylate), farnesyl transferase inhibitors (e.g., R115777), and other agents are reviewed, in addition to the potential roles of autologous and allogeneic SCT.

Original languageEnglish (US)
Pages (from-to)32-43
Number of pages12
Issue number1
StatePublished - Jan 1 2005


  • Idiopathic myelofibrosis
  • Myeloid metaplasia
  • Thalidomide
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'New approaches in the treatment of myelofibrosis'. Together they form a unique fingerprint.

Cite this